PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel $^{64}$Cu-DOTA-Knottin Peptide

Carsten H. Nielsen$^{1,5}$, Richard H. Kimura$^1$, Nadia Withofs$^1$, Phuoc T. Tran$^{3,4}$, Zheng Miao$^1$, Jennifer R. Cochran$^2$, Zhen Cheng$^1$, Dean Felsher$^3$, Andreas Kjær$^5$, Juergen K. Willmann$^1$, and Sanjiv S. Gambhir$^{1,2}$

Abstract

Due to the high mortality of lung cancer, there is a critical need to develop diagnostic procedures enabling early detection of the disease while at a curable stage. Targeted molecular imaging builds on the positive attributes of positron emission tomography/computed tomography (PET/CT) to allow for a noninvasive detection and characterization of smaller lung nodules, thus increasing the chances of positive treatment outcome. In this study, we investigate the ability to characterize lung tumors that spontaneously arise in a transgenic mouse model. The tumors are first identified with small animal CT followed by characterization with the use of small animal PET with a novel $^{64}$Cu–1,4,7,10-tetra-azacylododecane-N,N',N'',N'''-tetraacetic acid (DOTA)–knottin peptide that targets integrins upregulated during angiogenesis on the tumor associated neovasculature. The imaging results obtained with the knottin peptide are compared with standard $^{18}$F-fluorodeoxyglucose (FDG) PET small animal imaging. Lung nodules as small as 3 mm in diameter were successfully identified in the transgenic mice by small animal CT, and both $^{64}$Cu-DOTA-knottin 2.5F and FDG were able to differentiate lung nodules from the surrounding tissues. Uptake and retention of the $^{64}$Cu-DOTA-knottin 2.5F tracer in the lung tumors combined with a low background in the thorax resulted in a statistically higher tumor to background (normal lung) ratio compared with FDG (6.01 ± 0.61 versus 4.36 ± 0.68; $P < 0.05$). Ex vivo biodistribution showed $^{64}$Cu-DOTA-knottin 2.5F to have a fast renal clearance combined with low nonspecific accumulation in the thorax. Collectively, these results show $^{64}$Cu-DOTA-knottin 2.5F to be a promising candidate for clinical translation for earlier detection and improved characterization of lung cancer.

Introduction

Despite advances in cancer management and treatment, the mortality due to lung cancer is still strikingly high with an average 5-year survival of only 15% (1). The major contributor to the high mortality is diagnosis at a stage when the likelihood of effective treatment is low (2–4). Therefore, there is a need to develop technologies that will aid in the earlier detection of lung nodules (e.g., molecular imaging probes that are able to detect small tumors early in disease).

Low-dose computed tomography (CT) is increasingly utilized for screening patients with a high risk of developing lung cancer. CT screening has a high sensitivity (median, 96%; range, 81-100%; ref. 5) and can detect lung lesions in the sub-centimeter range but is limited by a relatively low specificity (median, 82%; range, 50-95%; ref. 5), resulting in frequent false-positive screening results (5, 6). Combined positron emission tomography (PET) and CT with $^{18}$fluorodeoxyglucose (FDG) can differentiate benign from malignant lesions >1 cm in diameter with high sensitivity and reasonably good specificity (6–8). However, noninvasive characterization of smaller lesions with $^{18}$FDG-PET/CT remains challenging due to the low volume of tumor, the partial volume effect, and inherent background from metabolic active tissues in the region of interest. Invasive procedures, such as thin-needle biopsy, are difficult to do because of the small lesion size and number of potential lesions to biopsy, and challenging due to the associated high risk of missed sampling (7, 9–12). As clinical PET/CT scanners continue to improve in spatial resolution and sensitivity, there is an opportunity to improve tumor detection/management with better tracers. A targeted imaging modality offers the opportunity to expand on the positive attributes of PET/CT and allows for a noninvasive detection and characterization of smaller lung nodules, thus increasing the chances of positive treatment outcome.

Once a tumor grows beyond 1 to 2 mm in diameter, it becomes dependent on angiogenesis to support its growth (13, 14). Imaging probes that target cell surface markers...
related to angiogenesis, such as integrins, show potential for early cancer detection (15, 16). Integrins are a family of transmembrane-bound receptors consisting of α and β subunits noncovalently linked as heterodimers. Integrins are involved in cell-to-cell and cell-to-extracellular matrix adhesion, and play a major role in cell migration processes, such as angiogenesis and metastasis. Expression of integrins, particularly, αvβ3, αvβ5, and α5β1, are significantly upregulated on tumor neovasculature and many tumor cells compared with quiescent endothelium and normal tissue (14–17), making them a promising target for differentiating tumor from normal vasculature.

In this study, we investigated the ability to image and characterize lung tumors that spontaneously arise in a transgenic mouse model. The tumors were first identified with small animal CT followed by characterization with the use of small animal PET with our novel 64Cu–1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)–knottin peptide engineered to bind integrin receptors with high affinity. Knottins, also known as cystine knots, are 20 to 60 amino acid peptides that consist of at least three interwoven disulfide bonds, imparting high thermal and proteolytic stability (18). Previously, we used the Ecballium elaterium trypsin inhibitor II (EETI-II), a knottin from the squash family of protease inhibitors, as a molecular scaffold to engineer peptides that bind with high affinity to tumor-related integrin receptors (17). We showed that the EETI-II–based knottin peptide 2.5F, which contains an Arg-Gly-Asp (RGD) motif, binds a range of integrins subtypes (αvβ3, αvβ5, and α5β1) with affinities in the low nmol/L range and developed it as a promising new probe for molecular imaging applications in living subjects (19).

The conditional transgenic mouse model used in this study spontaneously develops lung tumors upon activation of the K-Ras and MYC oncogenes upon the administration of doxycycline (20). Lung tumor status was serially monitored by small animal CT screening, and mice with CT-positive lung lesions were further examined with the use of small animal PET. Comparative PET imaging was done with 64Cu-DOTA-knottin 2.5F and 18F-FDG (Fig. 1). Both probes were able to identify lung tumors seen on CT. Uptake and retention of the 64Cu-DOTA-knottin 2.5F tracer in the lung tumor combined with a low background in the thorax resulted in a statistically higher tumor to background (normal lung) ratio compared with FDG, which shows the potential of 64Cu-DOTA-knottin 2.5F to be a promising candidate for clinical translation for earlier detection and improved characterization of lung cancer.

Materials and Methods

Transgenic mouse model

A detailed description of the generation of the transgenic mouse model and genotyping by PCR has been previously
described (20, 21). Briefly, the transgenic mouse model used in the study was established by crossing transgenic lines containing the Clara cell secretory protein (CCSP) promoter driving the reverse tetracycline transactivating protein (rtTA), a MYC line under the control of the tetracycline-responsive operon (TetO) and a mutant KrasG12D line under control of TetO. The desired result was the biconditional model CCSP-rtTa/TetO–MYC/TetO- KrasG12D.

Expression of the MYC and KrasG12D oncogenes was activated by weekly administration of 100 mg/mL doxycycline (Sigma) to the drinking water. Activation was initiated after weaning, typically 4 to 6 weeks of age, and tumors developed with an average latency of 36 weeks. All animal procedures were carried out according to a protocol approved by the Stanford University Administrative Panels on Laboratory Animal Care.

Small animal CT
Small animal CT scans were done with the use of a custom GE Medical Systems eXplore RS MicroCT System cone-beam scanner (GE Medical Systems). Seven transgenic mice with activated MYC and KrasG12D underwent serial small animal CT screening weekly for 3 weeks. Mice were anesthetized with 2% isofluorane in 2 L/min oxygen and positioned prone. Images were acquired at 97 μm resolution with a 70 kV (40 μA) beam, 12 ms exposure, and 400 radial views over a 360-degree rotation. The respiration was monitored during the scan with a BioVet monitoring system (m2m Imaging Corp.) and the acquisitions triggered to the end of the inspiratory phase.

Radiotracers
Synthesis and radiolabeling of the knottin 2.5F probe was done as previously described by us (19). 18F-FDG was supplied by the cyclotron and radiochemistry facility at Stanford University with high specific activity.

Stability of 64Cu-DOTA-knottin 2.5F
64Cu-DOTA-knottin 2.5F in PBS was incubated in an equal volume of mouse serum at 37°C and analyzed at 1 and 4 hours after incubation. At the indicated time points, one volume of solvent A (99.9% H2O and 0.1% trifluoroacetic acid) and one volume of dimethylformamide (Sigma) were added, and the resulting solution was centrifuged and filtered with a 0.2-micron spin filter (Corning). This mixture was analyzed by radio high-performance liquid chromatography (HPLC). Urine samples collected from mice 1 hour post-injection of 64Cu-DOTA-knottin 2.5F was diluted to 1 mL with solvent A and analyzed by radio HPLC.

Ex vivo biodistribution
Healthy mice (N = 5) were anesthetized and injected with 66.3 to 70.6 μCi (2.45-2.61 MBq) of 64Cu-DOTA-knottin 2.5F in 150 μL PBS through the tail vein and were euthanized 1 hour post-injection. The urine from 3 mice was collected for metabolite analysis by radio HPLC. Blood, heart, liver, lungs, muscle kidneys, spleen, brain, intestine, stomach, pancreas, and bone were removed and weighed. The radioactivity of each organ was measured by gamma counting and the activity level expressed as percent-injected dose/g tissue (%ID/g) or percent-injected dose/cm3 (%ID/cm3) for soft tissue and the lungs. Soft tissue was assumed to have a density of 1 g/cm3. Before injection of the tracer, the mice (N = 5) underwent small animal CT. The densities of the lungs were calculated by dividing the weight of the lungs with the volumes estimated by CT.

Small animal PET/CT
A R4 microPET (Siemens Medical Solutions USA, Inc.) was used for small animal PET imaging. Mice with CT-positive nodules underwent PET imaging with 18F-FDG on day 0 (relative to CT scan) and with 64Cu-DOTA-knottin 2.5F on day 1. Mice were anesthetized with 2% isofluorane in 2 L/min oxygen and injected with 93 to 115 μCi (3.44-4.26 MBq) of either 18F-FDG or 64Cu-DOTA-knottin 2.5F in 150 μL PBS through the tail vein. Mice were placed in a holder with four fiducial markers, each containing ~0.5 μCi of either 18F-FDG or 64Cu-DOTA-knottin 2.5F in 10 μL iodine solution (30 mg/mL). Before the PET scan mice underwent small animal CT scanning as described above, followed by a 15-minute prone PET acquisition ~60 minutes post-injection of tracer. For 18F-FDG-PET, mice were maintained under anesthesia in between injection and imaging. During anesthesia mice were kept warm on a heating pad. For knottin 2.5F, mice were allowed to recover from anesthesia in between injection and scanning. PET images were reconstructed with the use of the two-dimensional ordered subsets expectation maximization algorithm with a spatial resolution of 1.66 to 1.85 mm (22). No attenuation correction or partial volume corrections were applied.

Data analysis
All imaging data were analyzed offline with the use of software developed in our laboratory (AMIDE version 0.8.22; ref. 23), and the 3D volume viewer and analysis software (MicroView). Small animal PET/CT images were coregistered by manually identifying the center of the fiducial markers in the CT and PET images, and applying a built-in function for coregistration in the software. Regions of interest (ROIs) were subsequently drawn over the nodules and healthy lung tissue based on the CT images. Voxel values were converted to μCi/cm3 by multiplying with a cylindrical factor obtained by scanning a cylindrical phantom with a known concentration of activity. For each ROI, the mean uptake as %ID/g was calculated assuming a tissue density of 1 g/cm3. For each nodule the tumor-to-background ratio was calculated. The volumes of the lungs were estimated by drawing a rough ROI over the thorax of the mouse followed by simple binning to include only voxels with CT values corresponding to lung tissue.

Immunofluorescence
A subset of the mice (N = 4) were sacrificed immediately after 64Cu-DOTA-knottin 2.5F PET imaging. The lungs were removed and dissected into pieces containing tumor tissue and lung tissue without visible tumor mass. The tissue pieces were embedded in optimal cutting temperature compound and flash frozen on dry ice. Frozen blocks were sectioned at 10 microns and mounted on charged glass slides for
immunofluorescence. A double-staining procedure was applied to visualize endothelial cells (CD31) and integrins (αv-subunit). The following were used to stain for CD31: a rat anti-mouse CD31 primary antibody diluted 1:100 (BD Biosciences), a goat anti-rat biotinylated secondary antibody diluted 1:500 (Jackson ImmunoResearch Laboratories), and streptavidin-conjugated Alexa Fluor 488 diluted 1:200 (Invitrogen). The following were used to stain for αv: a rat anti-mouse αv-biotinylated primary antibody diluted 1:200 (Jackson ImmunoResearch Laboratories) and streptavidin-conjugated Alexa Fluor 594 diluted 1:200 (Invitrogen). Fluorescent images were acquired with a microscope (Axiophot, Carl Zeiss).

**Statistical analysis**

Data are given as mean ± SEM unless stated otherwise. The difference between the knottin 2.5F and FDG tumor-to-background ratios was assessed with the use of the two-sided Mann-Whitney test. A P-value <0.05 was considered statistically significant.

**Results**

**Small animal CT screening**

All seven transgenic mice that underwent serial small animal CT screening for 3 weeks were identified to have positive CT lung lesions. Next, we investigated the stability and biodistribution of the $^{64}$Cu-DOTA-knottin 2.5F tracer before using it in a comparative study to characterize the lung lesions with the use of FDG and $^{64}$Cu-DOTA-knottin 2.5F PET.

**Serum and in vivo stability of knottin 2.5F**

$^{64}$Cu-DOTA-knottin 2.5F incubated in mouse serum and urine samples from mice injected with $^{64}$Cu-DOTA-knottin 2.5F were analyzed by radio HPLC to test the stability of the probe under physiologically relevant environments. All samples show a major elution peak at 14 minutes corresponding to the intact probe. The probe is mainly excreted intact in urine, and it is highly stable after 4 hours of serum incubation (Supplementary Fig. S1). Overall, the radio-HPLC analysis showed that the probe is stable at the conditions tested and is suitable as an in vivo imaging probe.

**Ex vivo biodistribution**

The biodistribution of $^{64}$Cu-DOTA-knottin 2.5F was investigated in healthy mice 1 hour post-injection. The tracer cleared rapidly through the kidneys (11.43 ± 1.45%ID/cm$^3$). Modest levels of background activity were observed in the stomach, intestine, spleen, and liver (1.28-2.53%ID/cm$^3$) in agreement with previous reports (19). Lower background signal was seen in the brain, blood, muscle, pancreas, lungs, and heart (0.04-0.50%ID/cm$^3$).

**Small animal PET/CT**

Mice with CT-positive tumors underwent PET imaging with $^{18}$F-FDG and with $^{64}$Cu-DOTA-knottin 2.5F. For both tracers, differentiation of lung nodules from surrounding lung tissue was possible based on PET images obtained 1 hour post-injection. However, in a few cases ($N = 3$), in which the nodules were in close proximity to the heart, delineation of nodule boundaries was very difficult with FDG-PET. This was due to relatively high $^{18}$F-FDG uptake in the heart (26.92 ± 2.74%ID/g), leading to a spillover effect into the surrounding tissue. Importantly however, nodules that were obscured by high $^{18}$F-FDG heart spillover were clearly visible on the $^{64}$Cu-DOTA-knottin 2.5F images (Fig. 3). These images were made possible because of the low thoracic background signal that is characteristic of knottin peptides [18].

Overall, the radioactivity uptake in the nodules, measured as %ID/g by ROI analysis, was higher for $^{18}$F-FDG compared with $^{64}$Cu-DOTA-knottin 2.5F (Supplementary Fig. S2). However, ROI analysis of 10 distinguishable tumors showed a higher tumor-to-background ratio for the $^{64}$Cu-DOTA-knottin 2.5F tracer compared with FDG (Table 1). The tumor-to-background ratio was 6.01 ± 0.61 (range, 3.51-9.05) for $^{64}$Cu-DOTA-knottin 2.5F, which was significantly higher than the ratio obtained with FDG, 4.36 ± 0.68 (range, 1.70-8.30);

---

**Figure 2.** Ex vivo biodistribution of $^{64}$Cu-DOTA-knottin 2.5F. The biodistribution of knottin 2.5F in healthy mice ($N = 5$) 1 hour post-injection. Uptake expressed as %ID/g (left) and %ID/cm$^3$ (right); error bars, SEM.
Higher tumor-to-background ratios of $^{64}$Cu-DOTA-knottin 2.5F result from low background in the thorax, which facilitates nodule identification in regions made inaccessible by higher background $^{18}$F-FDG uptake (0.30 ± 0.03%ID/g for $^{64}$Cu-DOTA-knottin 2.5F versus 1.35 ± 0.13%ID/g for FDG; Fig. 5 and Supplementary Fig. S2).

Immunofluorescence

Mouse lung with nodules identified with $^{64}$Cu-DOTA-knottin 2.5F PET were double-stained for mouse CD31, a marker expressed on endothelial cells, and $\alpha_v$-integrin subunit to confirm the presence of the imaging target. Immunofluorescence showed colocalization of CD31 and $\alpha_v$, (Fig. 5), which confirms the presence of the imaging target on the tumor vasculature.

Discussion

Despite advances in diagnostic clinical imaging, there is a critical need for new imaging agents and new methods that allow noninvasive characterization of lung lesions in the subcentimeter range. Engineered knottin peptides have recently been validated by our group to specifically image integrin-expressing tumors in xenograft mouse models (17, 19, 24–27). Here we expand on our previous work and show that we can characterize spontaneous lung tumors developing in a conditional transgenic mouse model with the use of $^{64}$Cu-DOTA-knottin 2.5F and combined small animal PET/CT. These transgenic mouse models provide a unique opportunity to study tumorigenesis in a lung cancer model that more closely resembles the "natural" development and progression of human cancer. Because there is always an underlying concern with the use of artificial xenografts.

Figure 4. Tumor-to-background ratio of knottin 2.5F and FDG. ROIs were drawn over tumors ($N = 10$) and areas in the lungs without visible tumor mass on CT (background). For each ROI the mean uptake in %ID/g was estimated and the tumor-to-background ratio calculated. Bars, mean ± SEM. *, $P < 0.05$ for two-sided Mann-Whitney test.
models (28, 29), these studies provide additional information that will aid in clinical translation of newly developed molecular imaging probes.

The performance of knottin 2.5F, a peptide engineered to target integrin receptors, was compared with that of 18 F-FDG. We were able to obtain a higher tumor-to-background ratio with 64Cu-DOTA-knottin 2.5F compared with 18F-FDG (6.01 ± 0.61 versus 4.36 ± 0.68; \( P < 0.05 \)) due to a low background signal in the area of interest. It has previously been reported that anesthesia does not influence the tumor uptake of FDG (30). It is unlikely that the difference in tumor-to-background ratio can be addressed to the difference in anesthetic regiment between the two probes during PET imaging. Lung lesions imaged with 64Cu-DOTA-knottin 2.5F are clearly visible, allowing for easier image interpretation compared with 18F-FDG due to a large spillover effect from uptake in the heart. However, it is important to note that in a few cases, the quantification of 18F-FDG uptake is biased toward a higher tumor uptake because of this spillover from the heart to the adjacent lung tumors. The presence of the \( \alpha_v \)-integrin imaging target on the tumor neovasculature was confirmed by \textit{ex vivo} fluorescence microscopy. Furthermore, in a previous study we determined the specificity of integrin-binding knottin probes by competition with an excess of unlabeled peptide (19). Collectively, our results indicate that engineered knottin peptides are able to provide detailed molecular information about receptors expressed on vascular endothelium and the surface of tumors. Studies that use dynamic PET imaging and compartment modeling are in progress to investigate the fraction of the signal originating from knottins bound to integrins on the endothelium compared with the surface of the tumor.

### Table 1. Results of quantitative ROI analysis

<table>
<thead>
<tr>
<th>Tumor No.</th>
<th>Uptake (%ID/g)</th>
<th>Tumor-to-background</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Knottin 2.5F</td>
<td>FDG</td>
</tr>
<tr>
<td>1</td>
<td>2.36</td>
<td>14.9</td>
</tr>
<tr>
<td>2</td>
<td>1.65</td>
<td>5.10</td>
</tr>
<tr>
<td>3</td>
<td>1.30</td>
<td>5.10</td>
</tr>
<tr>
<td>4</td>
<td>1.39</td>
<td>7.08</td>
</tr>
<tr>
<td>5</td>
<td>1.75</td>
<td>5.33</td>
</tr>
<tr>
<td>6</td>
<td>2.03</td>
<td>4.60</td>
</tr>
<tr>
<td>7</td>
<td>2.12</td>
<td>8.72</td>
</tr>
<tr>
<td>8</td>
<td>1.99</td>
<td>5.10</td>
</tr>
<tr>
<td>9</td>
<td>1.38</td>
<td>4.46</td>
</tr>
<tr>
<td>10</td>
<td>1.66</td>
<td>2.41</td>
</tr>
<tr>
<td>( \bar{X} )</td>
<td>1.76</td>
<td>6.28</td>
</tr>
<tr>
<td>( SE_{\bar{X}} )</td>
<td>0.11</td>
<td>1.09</td>
</tr>
</tbody>
</table>

Figure 5. A, volume renderings of the thorax of a mouse imaged with FDG (left) and knottin 2.5F (right). A nodule is present immediately adjacent to the heart and is clearly visible when knottin 2.5F is used. The intense FDG uptake in the heart makes it impossible to delineate the nodule. Movies of the volume rendering images are available online as supplementary material. B, immunofluorescence of tumor sections. Sections were stained for CD31 (left) and \( \alpha_v \)-integrin (center). Merging of the two images (right) shows that the expression of \( \alpha_v \)-integrin colocalizes with the expression of the CD31 on the vessels (arrows).
Clinical studies with radiolabeled RGD peptides (\(^{18}\)F-galacto-RGD and \(^{18}\)F-AH111585) for PET imaging have shown the feasibility of imaging integrin receptors expressed on tumor cells and tumor neovasculature in cancer patients (17, 31–35). In addition, recent studies show that the pharmacokinetics of integrin-targeting peptides may easily be fine-tuned (19, 36, 37). For example, in an orthotopic lung cancer mouse model, PET imaging with \(^{64}\)Cu-DOTA–labeled PEGylated dimeric cyclic RGD peptide showed better tumor delineation compared with imaging with \(^{18}\)F-FDG. These studies show the potential of integrin imaging for early diagnosis and primary staging of lung cancer (15).

An important characteristic of any imaging probe is its uptake efficiency at the tumor site and its lack of accumulation at nontumor sites. The optimal probe will have high affinity for the target of interest, leading to high uptake, and at the same time show minimal background accumulation (38). Significant work has been put into engineering multimeric RGD peptide probes with increased affinity toward integrins. Multimeric RGD peptide probes show higher tumor accumulation and retention in vivo, but are also accompanied by and increase uptake in nontumor tissues (36, 39, 40). In contrast, engineering of the knottin scaffold with the monomeric RGD binding motif shows comparable affinity toward integrins as the tetrameric RGD peptide \(^{64}\)Cu-DOTA-E-[E[c(RGDfK)]\(_2\)]\(_2\) while maintaining a low accumulation in normal tissues, leading to a higher tumor-to-nontumor tissue ratio (Supplementary Table S1).

A common criterion for diagnosing malignancy with FDG-PET clinically is the standardized uptake value, which is a measure of the absolute uptake in a given region normalized for injected dose and body mass. However, it has been reported that using the tumor-to-background ratio improves the sensitivity of FDG-PET for diagnosis of small pulmonary nodules (7). In the current study, the absolute radiotracer uptake in the lung tumors was higher for FDG than for knottin 2.5F. This example shows that the comparatively better contrast shown by knottin 2.5F was due to lower background signal in the thorax for \(^{64}\)Cu-DOTA-knottin 2.5F compared with \(^{18}\)F-FDG. Together, the favorable biodistribution and tumor accumulation merit further investigation to see if these findings translate to the clinical setting.

Knottins have previously been shown to be nonimmunogenic, and a synthetic version of the knottin MVIIA (Ziconotide) is approved for treatment of chronic pain (19, 41). We have success fully done up to six imaging sessions over 8 months with \(^{64}\)Cu-DOTA-knottin 2.5F in immunocompetent mice without the observation of an acute immune response (data not shown). This shows that repeated imaging with \(^{64}\)Cu-DOTA-knottin 2.5F in mice is possible. However, rigorous toxicity studies will be required before clinical translation to minimize the possibility of an unexpected immunologic reaction against \(^{64}\)Cu-DOTA-knottin 2.5F.

The transgenic mouse model allows us to investigate if imaging of integrin expression with \(^{64}\)Cu-DOTA-knottin 2.5F can be used to characterize the lesions identified on CT as malignant. However, the difficulties of generating adequate numbers of transgenic mice with the right genotype and the inability to control the exact latency of tumor development after administration of doxycycline made a rigorous investigation of the tumor development at the earliest time impossible. Therefore, we were not able to investigate in detail the minimal detectable size of lung nodules that can be characterized as malignant by integrin imaging, but based on our data we were able to characterize nodules as small as 3 mm in diameter as malignant (Fig. 3). Some of the mice (\(N = 2\)) had lesions <3 mm in diameter visible on CT (\(N = 5\)). \(^{64}\)Cu-DOTA-knottin 2.5F was able to delineate one lesion with a diameter of 2.5 mm but missed the other small lesions, whereas FDG missed all of the lesions <3 mm in diameter. Assuming that all lesions detected by CT are true-positive findings, the sensitivity of \(^{64}\)Cu-DOTA-knottin 2.5F and FDG for all lesions is 73.3% and 66.7% respectively, and 100% for both probes for lesions >3 mm in diameter. Although we do not have histology to confirm the malignancy of the smaller lesions, we know from previous work that lung lesions detected by CT correspond with lung cancer (20). A possible explanation for failed detection of those small lesions by PET could be loss of contrast in the PET images due to blurring originating from respiratory motion during the PET acquisitions and partial volume effect. Unlike CT, no respiratory gating was applied during the PET acquisitions.

Because of the relative poor resolution of clinical PET scanners the partial volume effect becomes substantial for tumors in the subcentimeter range. For small tumors, partial volume effect will lead to underestimation of the true uptake and decreased sensitivity; however, with the use of mathematical models, it is possible to correct for partial volume effect. With a combination of morphologic information obtained from CT images, correction for respiratory motion, and low background signal from engineered peptides, such as \(^{64}\)Cu-DOTA-knottin 2.5F, partial volume effect–corrective algorithms will likely lead to better estimations of true uptake in lung nodules (42). Furthermore, clinical scanners with improved spatial resolution continue to be developed, which, if married to the right tracers, have significant potential for improved cancer diagnostics/management.

The clinical utility of \(^{64}\)Cu-DOTA-knottin 2.5F imaging will have to be carefully studied in patients with different types of lung cancer. If knottin 2.5F imaging is able to outperform FDG, it could replace FDG-PET. Alternatively, if the knottin 2.5F imaging agent is not able to do as well as FDG, then it could be used in cases in which FDG uptake is borderline, as indicated by an intermediate standardized uptake value. In these cases, FDG is unable to distinguish inflammation versus tumor, and the knottin 2.5F may help to do so.

In summary, our results show that engineered peptides, such as \(^{64}\)Cu-DOTA-knottin 2.5F, have the potential to be used in early detection of lung cancer. However, further studies are needed to address the smallest detectable tumor size by \(^{64}\)Cu-DOTA-knottin 2.5F. Further studies will also be needed to understand \(^{64}\)Cu-DOTA-knottin 2.5F uptake in sites of pulmonary infection and inflammation, which could lead to upregulation of integrins during the inflammatory process. Together with improvements in scanner spatial resolution/sensitivity, partial volume effect correction, and further engineering of knottins to
improve the tracer performance, PET imaging with engineered knottins might prove to be more sensitive than FDG-PET for primary diagnosis of lung lesions.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Pauline Chu for her kind help with tissue staining, the Stanford University Cyclotron and Radiochemistry Facility for synthesis of $^{18}$F-FDG, and Dr. Zhe Liu for his help with $^{18}$Cu radio labeling of the knottin peptide.

**References**


PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel $^{64}$Cu-DOTA-Knottin Peptide


Cancer Res 2010;70:9022-9030. Published OnlineFirst November 9, 2010.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-1338

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2010/11/05/0008-5472.CAN-10-1338.DC1

Cited articles  This article cites 40 articles, 13 of which you can access for free at: http://cancerres.aacrjournals.org/content/70/22/9022.full#ref-list-1

Citing articles  This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/70/22/9022.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/70/22/9022. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.